← Back to Search

2 cycles group for Colorectal Cancer (COPEC Trial)

Phase 3
Recruiting
Research Sponsored by West China Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 year after recruiting
Awards & highlights

COPEC Trial Summary

To compare the pathological effect between 2 cycles and 4 cycles of Capox regimen as neoadjuvant chemotherapy for low/ intermediate risk stage II/III rectal cancer.

Eligible Conditions
  • Colorectal Cancer
  • Chemotherapy

COPEC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 year after recruiting
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 year after recruiting for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
pathological Tumor Regression Grade evaluation
Secondary outcome measures
3-year overall survival
cumulative distant recurrence rate
cumulative local recurrence rate
+2 more

COPEC Trial Design

2Treatment groups
Experimental Treatment
Group I: 4 cycles groupExperimental Treatment1 Intervention
patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have two more cycles chemotherapy and TME operation after reevaluation and randomization.
Group II: 2 cycles groupExperimental Treatment1 Intervention
patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have TME operation after reevaluation and randomization.

Find a Location

Who is running the clinical trial?

Sichuan Provincial People's HospitalOTHER
91 Previous Clinical Trials
219,630 Total Patients Enrolled
Nanchong Central HospitalOTHER_GOV
14 Previous Clinical Trials
5,515 Total Patients Enrolled
Dazhou Central HospitalOTHER
1 Previous Clinical Trials
272 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
Ziqiang Wang,MD 2021. "Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04922853.
~85 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top